CN114574427A - 一种基于金黄色葡萄球菌的皮肤炎症体外评价模型的构建方法、评价模型及其应用 - Google Patents
一种基于金黄色葡萄球菌的皮肤炎症体外评价模型的构建方法、评价模型及其应用 Download PDFInfo
- Publication number
- CN114574427A CN114574427A CN202210111203.2A CN202210111203A CN114574427A CN 114574427 A CN114574427 A CN 114574427A CN 202210111203 A CN202210111203 A CN 202210111203A CN 114574427 A CN114574427 A CN 114574427A
- Authority
- CN
- China
- Prior art keywords
- inflammation
- staphylococcus aureus
- evaluation model
- hacat cells
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000191967 Staphylococcus aureus Species 0.000 title claims abstract description 71
- 238000013210 evaluation model Methods 0.000 title claims abstract description 50
- 201000004624 Dermatitis Diseases 0.000 title claims abstract description 37
- 238000000338 in vitro Methods 0.000 title claims abstract description 24
- 238000010276 construction Methods 0.000 title claims abstract description 19
- 206010061218 Inflammation Diseases 0.000 claims abstract description 132
- 239000003814 drug Substances 0.000 claims abstract description 25
- 230000008439 repair process Effects 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 19
- 230000000694 effects Effects 0.000 claims abstract description 16
- 238000012258 culturing Methods 0.000 claims abstract description 13
- 239000002537 cosmetic Substances 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 238000012216 screening Methods 0.000 claims abstract description 10
- 230000007246 mechanism Effects 0.000 claims abstract description 9
- 238000006243 chemical reaction Methods 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 5
- 230000010261 cell growth Effects 0.000 claims abstract description 4
- 238000007865 diluting Methods 0.000 claims abstract description 4
- 229940079593 drug Drugs 0.000 claims abstract description 4
- 230000008591 skin barrier function Effects 0.000 claims abstract description 4
- 238000012544 monitoring process Methods 0.000 claims abstract description 3
- 239000000047 product Substances 0.000 claims description 102
- 230000004054 inflammatory process Effects 0.000 claims description 62
- 239000006228 supernatant Substances 0.000 claims description 27
- 239000002609 medium Substances 0.000 claims description 23
- 102000000589 Interleukin-1 Human genes 0.000 claims description 20
- 108010002352 Interleukin-1 Proteins 0.000 claims description 20
- 238000004113 cell culture Methods 0.000 claims description 19
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 claims description 14
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 claims description 14
- 230000003698 anagen phase Effects 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 13
- 230000004083 survival effect Effects 0.000 claims description 12
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 11
- 230000008859 change Effects 0.000 claims description 8
- 241001052560 Thallis Species 0.000 claims description 6
- 238000004458 analytical method Methods 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 6
- 238000011156 evaluation Methods 0.000 claims description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 4
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 4
- 229960002986 dinoprostone Drugs 0.000 claims description 4
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 230000004663 cell proliferation Effects 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- 229960005322 streptomycin Drugs 0.000 claims description 3
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 239000012894 fetal calf serum Substances 0.000 claims description 2
- 102000057041 human TNF Human genes 0.000 claims description 2
- 230000004060 metabolic process Effects 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 154
- 239000000341 volatile oil Substances 0.000 description 53
- 230000002757 inflammatory effect Effects 0.000 description 41
- 230000028327 secretion Effects 0.000 description 22
- 210000003491 skin Anatomy 0.000 description 19
- 239000013641 positive control Substances 0.000 description 15
- 102000004890 Interleukin-8 Human genes 0.000 description 14
- 108090001007 Interleukin-8 Proteins 0.000 description 14
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 14
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 14
- 229940096397 interleukin-8 Drugs 0.000 description 14
- 239000013642 negative control Substances 0.000 description 14
- 230000000638 stimulation Effects 0.000 description 14
- 238000002965 ELISA Methods 0.000 description 12
- 240000000560 Citrus x paradisi Species 0.000 description 11
- 235000010672 Monarda didyma Nutrition 0.000 description 10
- 244000179970 Monarda didyma Species 0.000 description 10
- 239000006285 cell suspension Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 230000000770 proinflammatory effect Effects 0.000 description 9
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000028709 inflammatory response Effects 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 239000003642 reactive oxygen metabolite Substances 0.000 description 7
- 230000019491 signal transduction Effects 0.000 description 7
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 101000699762 Homo sapiens RNA 3'-terminal phosphate cyclase Proteins 0.000 description 6
- 102100029143 RNA 3'-terminal phosphate cyclase Human genes 0.000 description 6
- 235000011941 Tilia x europaea Nutrition 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 210000002510 keratinocyte Anatomy 0.000 description 6
- 239000004571 lime Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 102000003390 tumor necrosis factor Human genes 0.000 description 6
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 5
- 230000035605 chemotaxis Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 238000010195 expression analysis Methods 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 102000003945 NF-kappa B Human genes 0.000 description 4
- 108010057466 NF-kappa B Proteins 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 102000004125 Interleukin-1alpha Human genes 0.000 description 3
- 108010082786 Interleukin-1alpha Proteins 0.000 description 3
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102100035904 Caspase-1 Human genes 0.000 description 2
- 108090000426 Caspase-1 Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000005482 chemotactic factor Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 210000005007 innate immune system Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 231100000644 Toxic injury Toxicity 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- -1 small-molecule compounds Chemical class 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 208000015339 staphylococcus aureus infection Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
- C12N5/0629—Keratinocytes; Whole skin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/72—Undefined extracts from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/04—Immortalised cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210111203.2A CN114574427B (zh) | 2022-01-27 | 2022-01-27 | 一种基于金黄色葡萄球菌的皮肤炎症体外评价模型的构建方法、评价模型及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210111203.2A CN114574427B (zh) | 2022-01-27 | 2022-01-27 | 一种基于金黄色葡萄球菌的皮肤炎症体外评价模型的构建方法、评价模型及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114574427A true CN114574427A (zh) | 2022-06-03 |
CN114574427B CN114574427B (zh) | 2022-10-14 |
Family
ID=81772592
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210111203.2A Active CN114574427B (zh) | 2022-01-27 | 2022-01-27 | 一种基于金黄色葡萄球菌的皮肤炎症体外评价模型的构建方法、评价模型及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114574427B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111944756A (zh) * | 2020-08-06 | 2020-11-17 | 五邑大学 | 一种raw 264.7细胞炎症模型的建立方法 |
CN113684151A (zh) * | 2021-08-25 | 2021-11-23 | 上海珈凯生物科技有限公司 | 表皮葡萄球菌及其发酵培养和应用 |
-
2022
- 2022-01-27 CN CN202210111203.2A patent/CN114574427B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111944756A (zh) * | 2020-08-06 | 2020-11-17 | 五邑大学 | 一种raw 264.7细胞炎症模型的建立方法 |
CN113684151A (zh) * | 2021-08-25 | 2021-11-23 | 上海珈凯生物科技有限公司 | 表皮葡萄球菌及其发酵培养和应用 |
Non-Patent Citations (2)
Title |
---|
DIANA GUTIÉRREZ ET AL.: "Design and Selection of Engineered Lytic Proteins With Staphylococcus aureus Decolonizing Activity", 《FRONTIERS IN MICROBIOLOGY》 * |
JANINA EISENBEISA ET AL.: "The extracellular adherence protein (Eap) of Staphylococcus aureus acts as a proliferation and migration repressing factor that alters the cell morphology of keratinocytes", 《INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY》 * |
Also Published As
Publication number | Publication date |
---|---|
CN114574427B (zh) | 2022-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111544577B (zh) | 一种女性生殖护理制剂以及制备方法 | |
Le Bras et al. | Plasmodium falciparum: drug sensitivity in vitro of isolates before and after adaptation to continuous culture | |
CN114672443A (zh) | 一株具有预防或改善面部泛红和i型玫瑰痤疮功能的植物乳植杆菌 | |
CN103396995B (zh) | 一种筛选乳腺癌干细胞的三维培养方法 | |
CN104762364A (zh) | 黄芪多糖在拮抗奶牛乳腺上皮细胞凋亡中的应用方法 | |
CN112386665B (zh) | 天然原料的发酵液以及其用于制备抑制过敏反应或提升免疫力的组合物的用途 | |
CN114574427B (zh) | 一种基于金黄色葡萄球菌的皮肤炎症体外评价模型的构建方法、评价模型及其应用 | |
CN109172612A (zh) | 一种基于光合细菌的防治精神障碍的生物制剂及其应用 | |
CN102406858B (zh) | 一种消毒抗菌剂 | |
CN114711429A (zh) | 一株具有增强骨健康作用的罗伊氏乳杆菌及其应用 | |
CN114533723A (zh) | 一种调节骨骼肌糖代谢与线粒体生成的膳食营养补充剂及其应用 | |
CN103558392A (zh) | 一种基于炎症反应的抗动脉粥样硬化药效评价方法 | |
CN113181231A (zh) | 具有增强巨噬细胞吞噬活性功能的组合物及其应用和免疫药物 | |
Nasution et al. | An experiment for extracted Citrus hystrix leaf effectiveness on Pityrosporum ovale fungi growth | |
CN106265621B (zh) | 富马酸二甲酯在制备预防和治疗移植物抗宿主病及移植物抗白血病药物中的应用 | |
CN115969938B (zh) | 一种用于抑制由猪链球菌感染引起igf-1r转录水平上调的中药方剂的制备方法 | |
CN108130312B (zh) | 一种天麻素在抑制meth诱导sh-sy5y细胞自噬中的应用 | |
Mallik et al. | In vitro studies on antimicrobial and thrombolytic activity of Swietenia macrophylla King | |
CN114717131B (zh) | 一株对皮肤损伤具有保护作用的鼠李糖乳杆菌及其应用 | |
CN115590873B (zh) | 黄芩苷在制备抗伪狂犬病毒药物中的应用 | |
CN1927212B (zh) | 白藜芦醇苷用于制备治疗帕金森病药物的用途 | |
TWI723512B (zh) | 具有調節三酸甘油脂功能之組合物 | |
CN107233355B (zh) | 肉苁蓉多糖制备治疗缺血性脑卒中的药物的用途 | |
Saraswati et al. | PLGA-Collagen Composite Synthesis with the Antibacterial Addition of Jatropha curcas L. Leaf Extract as Absorbable Surgical Suture Candidate | |
CN107496904B (zh) | 多肽Lycosin-Ⅰ在制备抗炎和抗弓形虫药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20220620 Address after: 102488 Room 501, floor 5, building 1, yard 2, zhuoxiu North Street, Gongchen sub district office, Fangshan District, Beijing Applicant after: Tangyihuazhen Testing Technology (Beijing) Co.,Ltd. Applicant after: Tangyi Holdings (Shenzhen) Co.,Ltd. Address before: 102488 Room 501, floor 5, building 1, yard 2, zhuoxiu North Street, Gongchen sub district office, Fangshan District, Beijing Applicant before: Tangyihuazhen Testing Technology (Beijing) Co.,Ltd. Applicant before: Beijing Technology and Business University |
|
GR01 | Patent grant | ||
GR01 | Patent grant |